Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other Accumulated Expenses: 2011-2025

Historic Other Accumulated Expenses for Gyre Therapeutics (GYRE) over the last 10 years, with Sep 2025 value amounting to $228,000.

  • Gyre Therapeutics' Other Accumulated Expenses fell 82.30% to $228,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $228,000, marking a year-over-year decrease of 82.30%. This contributed to the annual value of $227,000 for FY2024, which is 83.42% down from last year.
  • As of Q3 2025, Gyre Therapeutics' Other Accumulated Expenses stood at $228,000, which was up 4.11% from $219,000 recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Other Accumulated Expenses ranged from a high of $8.1 million in Q3 2021 and a low of $118,000 during Q4 2022.
  • Its 3-year average for Other Accumulated Expenses is $921,182, with a median of $917,000 in 2023.
  • As far as peak fluctuations go, Gyre Therapeutics' Other Accumulated Expenses slumped by 97.77% in 2022, and later surged by 1,060.17% in 2023.
  • Quarterly analysis of 5 years shows Gyre Therapeutics' Other Accumulated Expenses stood at $4.1 million in 2021, then slumped by 97.10% to $118,000 in 2022, then soared by 1,060.17% to $1.4 million in 2023, then tumbled by 83.42% to $227,000 in 2024, then plummeted by 82.30% to $228,000 in 2025.
  • Its Other Accumulated Expenses stands at $228,000 for Q3 2025, versus $219,000 for Q2 2025 and $228,000 for Q1 2025.